Liver disease news - the latest biotech news from Labiotech.eu

First drug discovered through 3D bioprinted tissue disease model

Jim Cornall — Wed, 03 May 2023 12:37:43 +0000

Viscient Bio, Inc. has announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells. The company said it expects to develop the drug to treat non-alcoholic steatohepatitis (NASH), a growing epidemic disease that is believed to affect more than 10% of the U.S. […]

The post First drug discovered through 3D bioprinted tissue disease model appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Orphalan announces U.S. launch of drug to treat Wilson disease

Jim Cornall — Fri, 21 Apr 2023 09:30:00 +0000

Orphalan SA, an international orphan drug development and commercialization company, has announced the commercial launch in the U.S. for Cuvrior. Cuvrior is a new trientine tetrahydrochloride (TETA-4HCl). It is now available for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to D-penicillamine. Cuvrior was approved by the United States […]

The post Orphalan announces U.S. launch of drug to treat Wilson disease appeared first on Labiotech.eu.

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Jim Cornall — Fri, 31 Mar 2023 10:45:44 +0000

Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […]

The post Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China appeared first on Labiotech.eu.

Gut microbiota to be harnessed as a tool to diagnose diseases

Jim Cornall — Thu, 23 Mar 2023 11:30:00 +0000

A recent study at the University of Jyväskylä in Finland compared the gut microbiota and gut-derived metabolites between healthy controls and individuals with fatty liver. The results revealed that certain microbial metabolites are associated with liver fat content. The fact that the gut microbiota associates with many diseases has raised the hope that they could […]

The post Gut microbiota to be harnessed as a tool to diagnose diseases appeared first on Labiotech.eu.

Antibody candidate for treating serious liver disease

Jim Cornall — Tue, 07 Feb 2023 10:14:35 +0000

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […]

The post Antibody candidate for treating serious liver disease appeared first on Labiotech.eu.

Alcohol-related liver disease: mechanism could lead to new therapies

Jim Cornall — Tue, 24 Jan 2023 11:41:17 +0000

Alcohol-related liver disease is among the most common causes of morbidity and mortality worldwide. Due to an incomplete understanding of the factors contributing to disease development, liver transplantation is still the only available cure. A team led by Tim Hendrikx from MedUni Vienna’s Department of Laboratory Medicine has now uncovered a new mechanism that plays […]

The post Alcohol-related liver disease: mechanism could lead to new therapies appeared first on Labiotech.eu.

Vir Biotech presents new data for functional cure of chronic Hep B virus

Liza Laws — Tue, 08 Nov 2022 15:47:01 +0000

Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting was delivered in two oral presentations, both of which were selected […]

The post Vir Biotech presents new data for functional cure of chronic Hep B virus appeared first on Labiotech.eu.

Alimentiv and Summit collaborate to tackle liver disease NASH

Liza Laws — Fri, 04 Nov 2022 14:05:29 +0000

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

The post Alimentiv and Summit collaborate to tackle liver disease NASH appeared first on Labiotech.eu.

Biocartis starts European commercialization of liver cancer test

Jim Cornall — Mon, 10 Oct 2022 10:24:34 +0000

Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Portuguese biotech company Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with hepatocellular carcinoma (HCC). Herman Verrelst, chief executive officer of Biocartis, said: “We are […]

The post Biocartis starts European commercialization of liver cancer test appeared first on Labiotech.eu.

GENFIT to acquire Versantis to expand liver disease portfolio

Jim Cornall — Mon, 19 Sep 2022 10:52:03 +0000

GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […]

The post GENFIT to acquire Versantis to expand liver disease portfolio appeared first on Labiotech.eu.

Companies unite to bolster diagnostics for cancer and liver disease

Liza Laws — Tue, 28 Jun 2022 14:59:23 +0000

Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […]

The post Companies unite to bolster diagnostics for cancer and liver disease appeared first on Labiotech.eu.

Eiger BioPharmaceuticals presents liver study data

Jim Cornall — Tue, 28 Jun 2022 10:49:02 +0000

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 that took place June 22-26 in London, U.K. David Cory, […]

The post Eiger BioPharmaceuticals presents liver study data appeared first on Labiotech.eu.

Is a Treatment for NASH Finally on the Horizon?

Clara Rodríguez Fernández — Wed, 02 Mar 2022 07:40:00 +0000

Despite several high-profile trial failures in the field, multiple players are getting close to the approval stage with drug candidates for NASH, a ‘silent killer’ that affects the liver. Non-alcoholic steatohepatitis (NASH) is one of the most common reasons for liver transplantation. This condition consists of an abnormal buildup of fat in the liver that […]

The post Is a Treatment for NASH Finally on the Horizon? appeared first on Labiotech.eu.

Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration

Jonathan Smith — Wed, 19 Jan 2022 17:12:47 +0000

With the close of its Series A round at €48M ($54M), the tissue models company Engitix has shifted its business from providing drug discovery services to developing its own treatment pipeline for liver diseases. When Engitix was spun out of University College London in 2016, the startup primarily aimed to provide tissue models to pharmaceutical […]

The post Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration appeared first on Labiotech.eu.

Infographic: The Key Role of Imaging in Clinical Trials

Maya Chergova — Tue, 26 Jan 2021 09:00:05 +0000

Medical imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound have emerged as promising biomarkers in clinical trials. This brand new infographic, created in collaboration with Medpace, explores the different types of imaging techniques, their advantages, limitations, and how they can be successfully implemented in clinical trials. The use of medical […]

The post Infographic: The Key Role of Imaging in Clinical Trials appeared first on Labiotech.eu.

German Biotech Raises €11M to Regenerate Liver Damage

Clara Rodríguez Fernández — Tue, 21 Jan 2020 11:24:31 +0000

Biotech company HepaRegeniX has raised a Series B round that will allow its first candidate drug for liver disease to enter clinical trials later this year. Based in Tübingen, Germany, HepaRegenix was founded in 2017 with a €9M Series A round. The same investors are now taking part in a Series B round […]

The post German Biotech Raises €11M to Regenerate Liver Damage appeared first on Labiotech.eu.

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Jonathan Smith — Tue, 17 Dec 2019 11:52:41 +0000

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

The post Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial appeared first on Labiotech.eu.

Treating Liver Diseases: Is This Preclinical Model the Solution?

Larissa Warneck-Silvestrin — Wed, 04 Dec 2019 09:00:00 +0000

Liver diseases are on the rise. Although many drug candidates are being developed, preclinical toxicity, drug metabolism and drug-drug interaction studies remain challenging without a predictive model. One company is trying to address these difficulties with a full human liver preclinical model. Every year, two million people die of liver diseases worldwide. Common causes are […]

The post Treating Liver Diseases: Is This Preclinical Model the Solution? appeared first on Labiotech.eu.

Can This Cell Therapy Help Fight the NASH Epidemic?

Larissa Warneck-Silvestrin — Mon, 04 Nov 2019 09:00:39 +0000

Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) and is characterized by a fatty liver, inflammation, and liver cell damage. If left untreated, NASH can further develop into liver fibrosis, the formation of scar tissue in the liver, and liver cirrhosis. To date, a patient’s only option at the […]

The post Can This Cell Therapy Help Fight the NASH Epidemic? appeared first on Labiotech.eu.

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Jonathan Smith — Wed, 18 Sep 2019 09:10:18 +0000

Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of an ongoing phase I trial of Versantis’ lead candidate for the condition decompensated liver cirrhosis. Following this, the company will use the funds to launch […]

The post €15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II appeared first on Labiotech.eu.